CYP2C9 involvement in ACT‐453859 metabolism

@article{Ghin2015CYP2C9II,
  title={CYP2C9 involvement in ACT‐453859 metabolism},
  author={M. G{\'e}hin and J. Dingemanse and P. Sidharta},
  journal={The Journal of Clinical Pharmacology},
  year={2015},
  volume={55}
}
  • M. Géhin, J. Dingemanse, P. Sidharta
  • Published 2015
  • Medicine
  • The Journal of Clinical Pharmacology
  • WethankDrSrinivas for readingourpaper carefully, forhis positive general comments, and for raising some interesting discussion points. He indicated that the data described in our paper suggested a reducedmetabolism after an 800-mg single dose of ACT-453859. The metabolite-to-parent exposure ratios in the Multiple Ascending Dose (MAD) part are 0.48, 0.36, and 0.41 for the 10-, 100-, and 800-mg once daily dosing regimen, respectively, and, therefore, independent of dose. In the Single Ascending… CONTINUE READING

    Topics from this paper

    References

    SHOWING 1-2 OF 2 REFERENCES
    A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects
    • 15
    Development of a decision-making biomarker for CRTH2 antagonism in clinical studies
    • 7